Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 147

1.

Golgi protein GOLM1 is a tissue and urine biomarker of prostate cancer.

Varambally S, Laxman B, Mehra R, Cao Q, Dhanasekaran SM, Tomlins SA, Granger J, Vellaichamy A, Sreekumar A, Yu J, Gu W, Shen R, Ghosh D, Wright LM, Kladney RD, Kuefer R, Rubin MA, Fimmel CJ, Chinnaiyan AM.

Neoplasia. 2008 Nov;10(11):1285-94.

2.

Diagnostic significance of overexpression of Golgi membrane protein 1 in prostate cancer.

Li W, Wang X, Li B, Lu J, Chen G.

Urology. 2012 Oct;80(4):952.e1-7. doi: 10.1016/j.urology.2012.06.017. Epub 2012 Jul 25.

PMID:
22840862
3.

Zinc α2-glycoprotein as a potential novel urine biomarker for the early diagnosis of prostate cancer.

Katafigiotis I, Tyritzis SI, Stravodimos KG, Alamanis C, Pavlakis K, Vlahou A, Makridakis M, Katafigioti A, Garbis SD, Constantinides CA.

BJU Int. 2012 Dec;110(11 Pt B):E688-93. doi: 10.1111/j.1464-410X.2012.11501.x. Epub 2012 Sep 28.

4.

A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer.

Laxman B, Morris DS, Yu J, Siddiqui J, Cao J, Mehra R, Lonigro RJ, Tsodikov A, Wei JT, Tomlins SA, Chinnaiyan AM.

Cancer Res. 2008 Feb 1;68(3):645-9. doi: 10.1158/0008-5472.CAN-07-3224.

5.
6.

GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics.

Kristiansen G, Fritzsche FR, Wassermann K, Jäger C, Tölls A, Lein M, Stephan C, Jung K, Pilarsky C, Dietel M, Moch H.

Br J Cancer. 2008 Sep 16;99(6):939-48. doi: 10.1038/sj.bjc.6604614.

7.

Expression analysis of thrombospondin 2 in prostate cancer and benign prostatic hyperplasia.

Matos AR, Coutinho-Camillo CM, Thuler LC, Fonseca FP, Soares FA, Silva EA, Gimba ER.

Exp Mol Pathol. 2013 Jun;94(3):438-44. doi: 10.1016/j.yexmp.2013.02.002. Epub 2013 Mar 5.

PMID:
23470460
8.

The diagnostic value of PCA3 gene-based analysis of urine sediments after digital rectal examination for prostate cancer in a Chinese population.

Shen M, Chen W, Yu K, Chen Z, Zhou W, Lin X, Weng Z, Li C, Wu X, Tao Z.

Exp Mol Pathol. 2011 Feb;90(1):97-100. doi: 10.1016/j.yexmp.2010.10.009. Epub 2010 Oct 20.

PMID:
20970419
9.

WDR19 expression is increased in prostate cancer compared with normal cells, but low-intensity expression in cancers is associated with shorter time to biochemical failures and local recurrence.

Lin B, Utleg AG, Gravdal K, White JT, Halvorsen OJ, Lu W, True LD, Vessella R, Lange PH, Nelson PS, Hood L, Kalland KH, Akslen LA.

Clin Cancer Res. 2008 Mar 1;14(5):1397-406. doi: 10.1158/1078-0432.CCR-07-1535.

10.

Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy.

Rabien A, Burkhardt M, Jung M, Fritzsche F, Ringsdorf M, Schicktanz H, Loening SA, Kristiansen G, Jung K.

Eur Urol. 2007 May;51(5):1259-66. Epub 2006 Jun 14.

PMID:
16806661
11.

Quadriplex model enhances urine-based detection of prostate cancer.

Jamaspishvili T, Kral M, Khomeriki I, Vyhnankova V, Mgebrishvili G, Student V, Kolar Z, Bouchal J.

Prostate Cancer Prostatic Dis. 2011 Dec;14(4):354-60. doi: 10.1038/pcan.2011.32. Epub 2011 Jul 26.

PMID:
21788966
12.
13.

Up-regulation of cathepsin X in prostate cancer and prostatic intraepithelial neoplasia.

Nägler DK, Krüger S, Kellner A, Ziomek E, Menard R, Buhtz P, Krams M, Roessner A, Kellner U.

Prostate. 2004 Jul 1;60(2):109-19.

PMID:
15162377
14.

Analysis of gene expression in prostate cancer epithelial and interstitial stromal cells using laser capture microdissection.

Gregg JL, Brown KE, Mintz EM, Piontkivska H, Fraizer GC.

BMC Cancer. 2010 Apr 28;10:165. doi: 10.1186/1471-2407-10-165.

15.

Dicarbonyl/L-xylulose reductase: a potential biomarker identified by laser-capture microdissection-micro serial analysis of gene expression of human prostate adenocarcinoma.

Cho-Vega JH, Tsavachidis S, Do KA, Nakagawa J, Medeiros LJ, McDonnell TJ.

Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2615-22.

16.

Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer.

Ummanni R, Junker H, Zimmermann U, Venz S, Teller S, Giebel J, Scharf C, Woenckhaus C, Dombrowski F, Walther R.

Cancer Lett. 2008 Aug 8;266(2):171-85. doi: 10.1016/j.canlet.2008.02.047. Epub 2008 Apr 1.

PMID:
18384941
17.

Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker.

Darson MF, Pacelli A, Roche P, Rittenhouse HG, Wolfert RL, Young CY, Klee GG, Tindall DJ, Bostwick DG.

Urology. 1997 Jun;49(6):857-62.

PMID:
9187691
18.
20.

Overexpression of NSAID-activated gene product in prostate cancer.

Iczkowski KA, Pantazis CG.

Int J Surg Pathol. 2003 Jul;11(3):159-66.

PMID:
12894347
Items per page

Supplemental Content

Write to the Help Desk